My guess would be that the data is such that it is very close to a halt, and the DSMC is seeking advice from the FDA so as to not unintentionally derail a very important trial.

It may be another soft pitch by CYDY/DSMC (similar to CD10 when we asked what they thought before we formally requested EUA)

I dont have any confidence that this is what is occuring, but it is certainly a possibility.